PL3366307T3 - Kompozycje i sposoby hamowania masp-1 i/lub masp-2 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii - Google Patents

Kompozycje i sposoby hamowania masp-1 i/lub masp-2 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii

Info

Publication number
PL3366307T3
PL3366307T3 PL18158799T PL18158799T PL3366307T3 PL 3366307 T3 PL3366307 T3 PL 3366307T3 PL 18158799 T PL18158799 T PL 18158799T PL 18158799 T PL18158799 T PL 18158799T PL 3366307 T3 PL3366307 T3 PL 3366307T3
Authority
PL
Poland
Prior art keywords
masp
inhibting
compositions
treatment
methods
Prior art date
Application number
PL18158799T
Other languages
English (en)
Inventor
Hans-Wilhelm Schwaeble
Gregory Demopulos
Original Assignee
Omeros Corporation
University Of Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corporation, University Of Leicester filed Critical Omeros Corporation
Publication of PL3366307T3 publication Critical patent/PL3366307T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medicinal Preparation (AREA)
PL18158799T 2012-04-06 2013-04-05 Kompozycje i sposoby hamowania masp-1 i/lub masp-2 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii PL3366307T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261621461P 2012-04-06 2012-04-06
EP18158799.9A EP3366307B1 (en) 2012-04-06 2013-04-05 Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
EP13798222.9A EP2833907B1 (en) 2012-04-06 2013-04-05 Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
PCT/US2013/035488 WO2013180834A2 (en) 2012-04-06 2013-04-05 Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria

Publications (1)

Publication Number Publication Date
PL3366307T3 true PL3366307T3 (pl) 2022-03-07

Family

ID=49325295

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13798222T PL2833907T3 (pl) 2012-04-06 2013-04-05 Kompozycje i sposoby hamowania masp-1 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii
PL18158799T PL3366307T3 (pl) 2012-04-06 2013-04-05 Kompozycje i sposoby hamowania masp-1 i/lub masp-2 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13798222T PL2833907T3 (pl) 2012-04-06 2013-04-05 Kompozycje i sposoby hamowania masp-1 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii

Country Status (29)

Country Link
US (3) US20130273053A1 (pl)
EP (2) EP3366307B1 (pl)
JP (3) JP6366571B2 (pl)
KR (2) KR102142508B1 (pl)
CN (2) CN104661676A (pl)
AU (3) AU2013267909B2 (pl)
BR (1) BR112014024793A2 (pl)
CA (2) CA2869326C (pl)
CL (1) CL2014002694A1 (pl)
CY (1) CY1120736T1 (pl)
DK (2) DK3366307T3 (pl)
ES (2) ES2670668T3 (pl)
HR (1) HRP20180671T1 (pl)
HU (1) HUE036930T2 (pl)
IL (2) IL234991B (pl)
IN (1) IN2014KN02324A (pl)
LT (1) LT2833907T (pl)
MX (2) MX357540B (pl)
NO (1) NO2881536T3 (pl)
NZ (2) NZ629675A (pl)
PL (2) PL2833907T3 (pl)
PT (1) PT2833907T (pl)
RS (1) RS57266B1 (pl)
RU (2) RU2018114903A (pl)
SI (1) SI2833907T1 (pl)
SM (1) SMT201800253T1 (pl)
TR (1) TR201806939T4 (pl)
WO (1) WO2013180834A2 (pl)
ZA (1) ZA201408100B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX347691B (es) * 2011-05-04 2017-05-09 Omeros Corp Composiciones para inhibir la activacion del complemento dependiente de la masp-2.
CN115040653A (zh) * 2012-06-18 2022-09-13 奥默罗斯公司 抑制masp-1和/或masp-2和/或masp-3的组合物和方法
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
NZ629682A (en) * 2013-03-15 2017-03-31 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
TWI776827B (zh) 2016-11-28 2022-09-11 日商中外製藥股份有限公司 能夠調節配體結合活性的配體結合分子
AU2017364817B2 (en) 2016-11-28 2023-11-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
JP7409871B2 (ja) * 2017-04-03 2024-01-09 中外製薬株式会社 抗ｍａｓｐ－１抗体およびその使用方法
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
EP3719035A4 (en) 2017-11-28 2021-09-01 Chugai Seiyaku Kabushiki Kaisha POLYPEPTIDE WITH ANTIGEN-BINDING AREA AND CARRYING SECTION
WO2019231935A1 (en) * 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
US12077577B2 (en) 2018-05-30 2024-09-03 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
KR20220041846A (ko) * 2019-07-31 2022-04-01 바이오크리스트파마슈티컬즈,인코포레이티드 경구 보체 인자 d 억제제에 대한 투약 요법
EP4069238A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
EP4069676A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
CA3159172A1 (en) 2019-12-04 2021-06-10 Michael Cicirelli Masp-2 inhibitors and methods of use
EP3916385A1 (en) * 2020-05-26 2021-12-01 Dynamic Biosensors GmbH Cell immobilization in fluid flow at high flow velocities
EP4199954A4 (en) 2020-08-18 2024-12-25 Omeros Corporation Monoclonal antibodies, compositions and methods for detecting complement factor d
CN114295594B (zh) * 2021-12-06 2023-09-19 贵州理工学院 一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器
PY22106817A (es) * 2021-12-10 2023-12-21 Omeros Corp Anticuerpos terapéuticos que se unen al dominio serina-proteasa de masp-2 y usos de estos
CN121311247A (zh) * 2023-06-09 2026-01-09 舒泰神（北京）生物制药股份有限公司 特异性结合masp3的抗体以及特异性结合masp3和masp2的多特异性抗体

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
DE69030172T2 (de) 1990-01-26 1997-06-19 Immunomedics Inc Impfstoffe gegen Krebs und Infektionskrankheiten
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
CA2391402A1 (en) * 1999-12-02 2001-06-07 Jens Christian Jensenius Masp-3, a complement-fixing enzyme, and uses for it
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7043719B2 (en) * 2001-07-23 2006-05-09 Intel Corporation Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations
EP1531757B1 (en) 2002-07-19 2016-09-07 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
MXPA05008570A (es) * 2003-02-21 2005-11-04 Tanox Inc Metodos para la prevencion y tratamiento de danos tisulares asociados con una lesion por isquemia-reperfusion.
US20070253949A1 (en) * 2004-02-03 2007-11-01 Stefan Golz Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1)
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
DE602006004582D1 (de) * 2006-07-31 2009-02-12 Fiat Ricerche Durch eine Fluidströmung betätigbarer elektrischer Generator
JP5537420B2 (ja) 2007-05-31 2014-07-02 ユニヴァーシティ オブ ワシントン 標的遺伝子の誘導性変異誘発
CN102643345A (zh) * 2008-09-26 2012-08-22 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
JP2013516389A (ja) * 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
CA2753921A1 (en) * 2009-03-05 2010-09-10 Smith & Nephew, Inc. System, method, and apparatus for locating a femoral neck guide wire
EP3395828A1 (en) * 2009-07-17 2018-10-31 Rigshospitalet Inhibitors of complement activation
WO2011057158A1 (en) * 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
US8795973B2 (en) * 2010-11-29 2014-08-05 University of Leceister Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof
NZ731596A (en) * 2011-04-08 2022-07-01 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation

Also Published As

Publication number Publication date
JP2015514117A (ja) 2015-05-18
SMT201800253T1 (it) 2018-07-17
IL234991A0 (en) 2014-12-31
EP3366307B1 (en) 2021-07-28
DK2833907T3 (en) 2018-05-28
CY1120736T1 (el) 2019-12-11
SI2833907T1 (en) 2018-07-31
PT2833907T (pt) 2018-05-29
KR20150003785A (ko) 2015-01-09
DK3366307T3 (da) 2021-11-01
US20220242972A1 (en) 2022-08-04
HUE036930T2 (hu) 2018-08-28
PL2833907T3 (pl) 2018-08-31
HK1206996A1 (en) 2016-01-22
MX357540B (es) 2018-07-13
RU2018114903A (ru) 2019-03-04
CA2869326A1 (en) 2013-12-05
NO2881536T3 (pl) 2018-06-30
US20130273053A1 (en) 2013-10-17
NZ629675A (en) 2017-02-24
CA2869326C (en) 2021-09-21
HRP20180671T1 (hr) 2018-07-13
EP2833907B1 (en) 2018-02-28
MX2018008658A (es) 2021-10-19
RU2014144621A (ru) 2016-05-27
MX388278B (es) 2025-03-18
ES2894944T3 (es) 2022-02-16
ES2670668T3 (es) 2018-05-31
JP6366571B2 (ja) 2018-08-01
IN2014KN02324A (pl) 2015-05-01
MX2014012045A (es) 2015-05-15
TR201806939T4 (tr) 2018-06-21
CA3087933A1 (en) 2013-12-05
CN104661676A (zh) 2015-05-27
IL274721A (en) 2020-07-30
KR20200097808A (ko) 2020-08-19
CL2014002694A1 (es) 2015-08-28
AU2020204163A1 (en) 2020-07-09
AU2018200721B2 (en) 2020-03-26
CN121401408A (zh) 2026-01-27
US20190382505A1 (en) 2019-12-19
BR112014024793A2 (pt) 2019-08-27
EP2833907A2 (en) 2015-02-11
AU2013267909A1 (en) 2014-11-27
RU2655299C2 (ru) 2018-05-24
WO2013180834A2 (en) 2013-12-05
EP2833907A4 (en) 2016-03-16
KR102318623B1 (ko) 2021-11-02
LT2833907T (lt) 2018-06-11
IL234991B (en) 2020-06-30
ZA201408100B (en) 2022-05-25
EP3366307A1 (en) 2018-08-29
RS57266B1 (sr) 2018-08-31
JP2018162307A (ja) 2018-10-18
JP2021001199A (ja) 2021-01-07
RU2018114903A3 (pl) 2021-08-12
AU2018200721A1 (en) 2018-02-22
IL274721B (en) 2022-04-01
JP6815355B2 (ja) 2021-01-20
NZ781091A (en) 2022-04-29
KR102142508B1 (ko) 2020-08-10
NZ727063A (en) 2021-10-29
AU2013267909B2 (en) 2018-03-01
WO2013180834A3 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
PL2833907T3 (pl) Kompozycje i sposoby hamowania masp-1 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii
IL266582A (en) Preparations and methods for the treatment of hemoglobin diseases
EP2831001A4 (en) COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
EP2675469A4 (en) COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER
IL242483B (en) Preparations containing omomyc and their use for cancer treatment
ZA201408055B (en) Compositions and methods for the treatment of local pain
IL238177A0 (en) Methods and preparations for the treatment of cancer
EP2817018A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS
ZA201408056B (en) Compositions and methods for the treatment of mucositis
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
IL236823A0 (en) Preparations for use in the treatment of bone defects
PL3082845T3 (pl) Sposoby i kompozycje do leczenia neuropatii obwodowych
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
IL238126A0 (en) Compositions for the treatment and prevention of obesity
ZA201503844B (en) Compositions and methods for treating dental caries
IL238602A0 (en) Preparations and methods for the treatment of ectodermal dysplasia
ZA201500111B (en) Compositions and methods for enhancing the efficacy of contraceptive microbicides
EP2934501A4 (en) USES AND METHOD FOR THE TREATMENT OF LIVER DISEASES OR DRESSES
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
ZA201408065B (en) Compositions and methods for the treatment of diabetes
SG11201500838UA (en) Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna